In the SURMOUNT-5 trial, tirzepatide produced an average weight reduction of 20.2% (about 50 lbs) over 72 weeks, compared with 13.7% (about 33 lbs) for injectable semaglutide
GLP-1 helps regulate appetite and blood sugar, slows the rate at which our stomach empties, and helps our pancreas release insulin after eating
It is important that you are at home to receive the package
Lifestyle factors such as poor sleep, high stress levels, and alcohol consumption can also increase appetite
Peak plasma concentrations (Cmax) observed in human supplementation trials are often substantially lower than concentrations used in cell culture models
Administered once a week, Wegovy has helped participants lose up to 15% of their body weight in clinical trials